[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Oxford\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":660},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,95,0,25,[9,50,79,101,127,151,176,201,225,259,284,309,334,361,388,414,438,464,484,520,546,565,582,605,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100652303","multimodal-biomarkers-in-coronary-artery-disease-pathogenesis-the-oxford-acute-myocardial-infarction-study-oxami-study-100652303",false,"NCT07772570","Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study)","OXAMI","Inclusion Criteria:\n\n* Evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND\u002FOR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.\n\nExclusion Criteria:\n\n* Patients in whom safety or clinical concerns preclude participation.\n* Anaemia (Hb \\\u003C9).\n* Pregnant or breast feeding females.\n\nAdditional exclusion criteria for patients undergoing MRI\n\n* claustrophobia which limits \u002F prevents participants from remaining in MRI scanner.\n* patients who cannot lie flat on the scan table.\n* patients with metallic implants, pacemakers, implantable defibrillators etc, unless known to be MRI compatible.\n* patients with known allergy to medium of contrast (gadolinium)\n\nAdditional exclusion criteria for patients undergoing coronary CT angiography\n\n* patients with a known allergy to iodinated contrast media\n* eGFR\\\u003C 30 ml\u002Fmin (stage 3-5 renal disease)",true,"ALL","18 Years","90 Years",{"count":22,"type":23},2000,"ESTIMATED","20 Years","OBSERVATIONAL","Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Sometimes a plaque can suddenly break open, causing a blood clot to form and block the artery. This can lead to a heart attack and permanent damage to the heart muscle.\n\nAlthough much has been learned about coronary artery disease, important questions remain about why some plaques suddenly become unstable, how this affects blood flow through the smallest blood vessels of the heart, and why some patients develop more heart muscle damage than others.\n\nThe Oxford Acute Myocardial Infarction (OxAMI) research programme aims to improve our understanding of these processes. We will study both the disease within the coronary arteries (the \"upstream\" problem) and its effects on the heart muscle (the \"downstream\" damage). By examining these together, we hope to understand more clearly how changes in coronary plaques lead to heart injury and how this differs between patients.\n\nPatients undergoing procedures to investigate or treat coronary artery disease provide an important opportunity to study these processes. During coronary angioplasty (also called percutaneous coronary intervention or PCI), a narrow or blocked artery is opened, usually using a small balloon and a stent. This procedure can disturb the underlying plaque in a similar way to the plaque disruption that occurs during a heart attack. Where appropriate, we may therefore collect blood and material released from the plaque during these procedures. Blood may be collected from different locations in the circulation, allowing us to study substances released by the plaque and heart muscle. Material that would otherwise be discarded during treatment may also be collected for laboratory analysis.\n\nWe will use several established and newer techniques to examine the coronary arteries, the small blood vessels within the heart, and the heart muscle. These may include detailed imaging from inside the coronary arteries using intravascular ultrasound (IVUS) or optical coherence tomography (OCT). We may also measure blood pressure and flow within the coronary arteries to assess how well the small blood vessels supplying the heart are working.\n\nNon-invasive heart scans may include cardiovascular magnetic resonance (CMR\u002FMRI), cardiac computed tomography (CT) and echocardiography (ultrasound). These techniques can provide detailed information about the structure and function of the heart, blood supply to the heart muscle, areas of injury or permanent scarring, and changes that occur following a heart attack. In particular, MRI may help distinguish heart muscle that has been permanently damaged from muscle that is injured but could potentially recover after blood flow is restored. This may be especially important for patients who arrive at hospital several hours after their heart attack began.\n\nOther measurements may include electrocardiograms (ECGs), which record the electrical activity of the heart, and measurements of heart pressure, volume and function. Some participants may also have longer-term ECG monitoring.\n\nBlood and tissue samples may be analysed using a range of laboratory techniques. These studies will investigate inflammation, blood clotting and other biological processes involved in coronary artery disease and heart attacks. Newer laboratory methods may allow us to measure large numbers of proteins and small molecules in the blood. Material collected from plaques may also be examined under a microscope to identify its cells and structural components.\n\nWith additional consent, blood samples may be stored for genetic research. This could help us understand whether differences in people's genes influence their risk of coronary artery disease, their response to a heart attack, or the amount of heart damage that occurs.\n\nBy combining information about coronary plaques, blood flow through the heart's circulation, heart muscle injury, imaging, blood and tissue markers, and genetic factors, OxAMI aims to build a detailed picture of coronary artery disease and heart attacks. The programme will establish a carefully characterised group of research participants who may contribute to future OxAMI studies conducted under separate research protocols.\n\nUltimately, this research aims to identify better ways to predict, diagnose and understand coronary artery disease and heart attacks, and to identify new approaches that could improve treatment and outcomes for future patients.",[28,29,30,31,32,33,34,35,36],"Myocardial Injury","Atherosclerosis Cardiovascular Disease","Cardiac Imaging Techniques","Genetics","Thrombus","Trained Immunity","Biomarker Discovery","Coronary Physiology","Intravascular Imaging and Microvascular Obstruction","RECRUITING","2026-08-14",{"date":40,"type":41},"2026-08-19","ACTUAL",{"date":43,"type":41},"2012-05",{"date":45,"type":23},"2046-12",{"name":47,"class":48},"University of Oxford","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":49},"100652111","phase-4-study-of-the-effects-of-atomoxetine-on-motivation-100652111","NCT07771595","Study of the Effects of Atomoxetine on Motivation","The Effects of Single Dose Atomoxetine on Motivation and Information Processing","STEAM","Inclusion Criteria:\n\n* Age: 18-45\n* Good physical health\n* Willing and able to give informed consent to participate in the study\n* Sufficient knowledge of English language to understand and complete the study tasks\n\nExclusion Criteria:\n\n* Current DSM-5 axis-I diagnosis (based on SCID results at screening) or history of a severe psychological disorder such as psychotic disorder, bipolar disorder, alcohol or substance abuse, or post-traumatic stress disorder\n* Previous or current extended period of persistent thoughts about ending one's life (longer than 5 days) or previous suicide attempt\n* Clinical diagnosis of attention deficit hyperactivity disorder (ADHD) or on the waiting list for assessment\n* Any intake of CNS-medication in the last 6 weeks (including as part of another study)\n* Any current intake of blood pressure or other heart medication, including beta blockers\n* Any current or previous medical condition or medication intake (last month) of any medication that, in the opinion of the study medic, may interfere with the safety of the participant or the scientific integrity of the study.\n* Severely underweight (BMI \\\u003C17) or very obese (BMI \\>40), OR otherwise deemed unsuitable for the study due to weight-related concerns at the discretion of the study medic\n* History of cardiovascular, cerebrovascular disease\n* Breathing or lung-related illnesses, significant liver or kidney problems, or severe gastrointestinal conditions.\n* High blood pressure (defined as repeated measurements of blood pressure where either the systolic or the diastolic blood pressure, or both, are at or above 140\u002F90 mmHg (https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehy339)\n* History of recurrent rashes or history of allergic reactions to relevant substances (atomoxetine, placebo treatment)\n* Significant physical (including visual and auditory) or language impairment that would make complying with the study protocol challenging.\n* History of palpitations with sudden onset and offset,\n* History of fainting on exertion or in response to fright or loud noise\n* Family history of sudden death in a first-degree relative under 40 years of age\n* Women: pregnancy (as determined by a urine test), breast-feeding\n* Significant consumption of caffeine (more than about 6 cups of strong coffee per day), nicotine (more than 5 cigarettes per day, or equivalent amount), alcohol (more than two pints of beer a day or equivalent)\n* Participation in a study that involves the use of medication in the past 3 months\n* Participation in another study using similar tasks in the past 6 months","45 Years",{"count":60,"type":23},40,"INTERVENTIONAL",[63],"PHASE4","This study investigates how increasing noradrenaline levels with atomoxetine affects motivation and information processing relevant to apathy. Apathy, characterised by low motivation and reduced goal-directed behaviour, is common across neuropsychiatric disorders and is associated with poorer outcomes. Atomoxetine, a noradrenaline reuptake inhibitor, has been shown to influence effort, reward learning, and decision-making; however, its effects on cognitive processes relevant to apathy remain unclear.\n\nThis study will investigate how pharmacologically increasing noradrenaline levels with atomoxetine affects different components of motivation altered in apathy, including reward processing, effort-based decision-making, goal-directed behaviour, and learning.\n\nIn a within-subject, double-blind, placebo-controlled, randomised study, forty healthy participants with varying levels of apathy will complete a computerised task battery after receiving a single dose of atomoxetine (40 mg) and placebo. Validated tasks assessing motivation, reward learning, decision-making, goal-directed behaviour, and information processing will be used to examine whether and how atomoxetine influences motivation-related cognitive processes.",[66],"Apathy",[68,66,69,70],"Atomoxetine","Motivation","Reward Processing","NOT_YET_RECRUITING",{"date":73,"type":41},"2026-08-18",{"date":75,"type":23},"2026-08",{"date":77,"type":23},"2027-10",{"name":47,"class":48},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":17,"sex":18,"minAge":24,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100619537","environment-pathogens-and-host-interactions-in-melioidosis-100619537","NCT07345910","Environment, Pathogens, and Host Interactions in Melioidosis","Decoding the Triad: the Interplay Between Environment, Pathogen, and Host in Melioidosis (DeEPH)","DeEPH","Inclusion criteria for melioidosis patients:\n\n* Age ≥20 years\n* Positive for Burkholderia pseudomallei from any clinical samples\n* Resident of the study area for at least two years, including the follow-up period\n* Willing to participate and give informed consent.\n\nInclusion criteria for healthy controls:\n\n* Age ≥20 years\n* Currently healthy as judged by study doctor\n* Resident of the study area for at least two years, including the follow-up period\n* Willing to participate and give informed consent.\n\nInclusion criteria for sandbox residents:\n\n* Age ≥20 years\n* Resident of the study area for at least two years, including the follow-up period\n* Willing to participate and give informed consent.\n\nExclusion criteria for melioidosis patients:\n\n* Current tuberculosis (TB) or TB treatment within the past six months\n* Documented HIV infection or use of immunosuppressive therapy in the past 12 months\n\nExclusion criteria for healthy controls:\n\n* History of melioidosis\n* Significant acute illness\n* Current fever or soft tissue infection\n\nExclusion criteria for sandbox residents\n\n-N\u002FA",{"count":88,"type":23},2400,"This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.\n\nThe hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.\n\nFor each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.\n\nIn addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.\n\nThis study is funded by the Wellcome Trust. The grant reference number is 323077\u002FZ\u002F24\u002FZ",[91],"Melioidosis","2026-08-07",{"date":94,"type":41},"2026-08-10",{"date":96,"type":23},"2026-08-01",{"date":98,"type":23},"2034-12-01",{"name":47,"class":48},3,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":61,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":49},"100478539","improving-sleep-and-learning-in-rehabilitation-after-stroke-part-2-100478539","NCT05511285","Improving Sleep and Learning in Rehabilitation After Stroke, Part 2","INSPIRES-2","Inclusion Criteria:\n\n* Willing and able to give informed consent for participation in the study\n* Aged 18 years or above.\n* Clinical diagnosis of stroke affecting the upper limb, with sufficient movement to perform the motor learning task\n* Discharged from inpatient care\n* Interest in accessing a programme with the aim of improving sleep quality\n* Reliable access to the internet\n\nExclusion Criteria:\n\n* Other neurological condition affecting movement (e.g. Parkinson's Disease, Multiple Sclerosis)\n* Diagnosed, untreated, sleep disorder (e.g. Sleep Apnea)\n* Uncontrolled seizures\n* Planned inpatient admission (e.g. for rehabilitation) in the next 4 months that would impact ability to engage with the Sleepio programme\n* Engagement in psychological therapy for insomnia in the past 12 months\n* Pregnancy",{"count":109,"type":23},100,[111],"NA","This study will explore whether sleep in stroke survivors is improved with digital cognitive behavioural therapy for insomnia (Sleepio), in comparison to treatment as usual, and will explore whether changes in sleep relate to changes in overnight consolidation of motor learning.",[114],"Stroke",[116,117,118,119,120],"Sleep","Rehabilitation","Digital","Cognitive Behavioural Therapy for Insomnia","Motor consolidation",{"date":94,"type":41},{"date":123,"type":41},"2022-09-13",{"date":125,"type":23},"2027-12",{"name":47,"class":48},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":61,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":49},"100629113","phase-1-a-clinical-study-of-piperaquine-pyronaridine-and-artesunate-administered-in-combination-in-healthy-adults-100629113","NCT07470424","A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults","A Randomized, Open-Label Crossover Study to Evaluate Potential Pharmacokinetic Interactions of Orally Administered Piperaquine, Pyronaridine and Artesunate in Healthy Adult Participants","APP","Inclusion Criteria:\n\n1. Healthy as judged by a responsible physician with no abnormality identified on a medical evaluation including medical history and physical examination.\n2. Male or female non-smoker aged between 18 years to 60 years, weighting between 45 and 85 kg.\n3. A female is eligible to participate in this study if she is:\n\n   * of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or double oophorectomy\n   * or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone levels \\>40 mIU\u002FmL or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy\n   * or of childbearing potential, has a negative serum pregnancy test at screening and prior to start the study drug in each period, and agrees to abstain from sexual intercourse or use effective contraceptive methods (e.g., intrauterine device, hormonal contraceptive drug, tubal ligation or female barrier method with spermicide) during the study until completion of the follow-up procedures\n4. Normal electrocardiogram (ECG) with QTc \\\u003C450 msec.\n5. Willingness and ability to comply with the study protocol for the duration of the trial.\n6. Participants is willing and able to give written informed consent for participation in the study\n\nExclusion Criteria:\n\n1. Females who are pregnant, trying to get pregnant, or are lactating.\n2. The participant has evidence of active substance abuse that may compromise safety, pharmacokinetics, or ability to adhere with protocol instructions.\n3. A positive pre-study hepatitis B surface antigen, positive hepatitis C antibody, or positive human immunodeficiency virus-1 (HIV-1) antibody result at screening.\n4. Participants with a personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or additional risk factors for torsades de pointes (heart failure, hypokalemia) or with a family history of long QT syndrome, Brugada syndrome, or sudden cardiac death.\n5. Abnormal serum creatinine (Scr) and estimated glomerular filtration rate (eGFR) \\\u003C70 mL\u002Fmin as determined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation\n6. History of alcohol or substance abuse or dependence within 6 months of the study.\n7. Use of prescription or non-prescription drugs except paracetamol at doses of up to 2 grams\u002Fday, including vitamins, herbal and dietary supplements (including St. John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 times the drug half-life (whichever is longer) prior to the first dose of study medication until the completion of the follow-up procedure, unless in the opinion of the investigator, the medication will not interfere with the study procedures or compromise participant safety; the investigator will take advice from the manufacturer representative as necessary.\n8. The participant has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 times the drug half-life, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of study medication.\n9. The participant is unwilling to abstain from ingesting alcohol within 48 hours prior to the first dose of study medication until collection of the final pharmacokinetic sample during each regimen.\n10. Participants who have donated blood to the extent that participation in the study would result in more than 300 mL blood donated within a 30-day period. Note: This does not include plasma donation.\n11. Participants who have a history of allergy to the study drug or drugs of this class, or a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation in the trial. In addition, if heparin is used during pharmacokinetic sampling, participants with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.\n12. Lack of suitability for participation in this study, including but not limited to, unstable medical conditions, systemic disease manifested by tendency to granulocytopenia e.g. rheumatoid arthritis and lupus erythematosus that in the opinion of the investigator would compromise their participation in the trial.\n13. AST or ALT \\>1.5 times the upper limit of normal (ULN)\n14. History of antimalarial drugs use including but not limited to mefloquine, chloroquine, primaquine, artesunate, piperaquine and pyronaridine treatment within 6 months.","60 Years",{"count":137,"type":23},24,[139],"PHASE1","This is an open-label pharmacokinetic study in 24 healthy Thai participants. Participants will be admitted in the inpatient ward and each participant will attend a total of 4 visits, including one screening visit and three hospital admissions. Participants will be randomized into one of six groups.\n\nEach group will receive 3 drug regimens consisting of (1) piperaquine, (2) pyronaridine plus artesunate, or (3) piperaquine, pyronaridine, and artesunate, administered once per day for three consecutive days in different sequential orders.\n\nAfter each regimen, participants will be followed up for six weeks for clinical assessments and laboratory evaluations to study the pharmacokinetics. A washout period of at least eight weeks will be implemented between each regimen.\n\nThis study is funded by the Global Health Innovative Technology Fund (GHIT Fund), Tokyo, Japan, under grant number G2025-117.",[142],"Malaria","2026-08-04",{"date":145,"type":41},"2026-08-05",{"date":147,"type":23},"2026-11-01",{"date":149,"type":23},"2027-11-01",{"name":47,"class":48},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":49},"100643532","gut-leakage-in-dengue-100643532","NCT07602920","Gut Leakage' in Dengue","Gut Leakage and Sonographic Abdominal Changes in Hospitalized Dengue Patients: an Observational Study","GLiD","Inclusion Criteria:\n\nDengue participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Diagnosed as a case of Dengue on the basis of clinical features and positive NS1 antigen and\u002For IgM dengue antibody\n* Hospitalized in medicine or dengue ward in Chittagong Medical College Hospital.\n* Enrolled within 24 hours of hospitalization.\n\nHealthy participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Clinically healthy with no acute or chronic illness\n* Attendant of a dengue patient (not a patient)\n\nExclusion Criteria:\n\nDengue participants\n\n* Unable to provide consent or participate in follow-up procedures\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n\nHealthy participants\n\n* Unable to provide consent\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n* History of current or recent dengue or other arbo viral infection",{"count":160,"type":23},190,"Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the development of medical counter measures because of the high risk of it causing a Public Health Emergency of Intenational Concern (PHEIC). Warning signs for severe dengue, associated with mortality, include gastrointestinal features including abdominal pain, vomiting, and diarrhoea. Multiple alterations may occur in in the gastrointestinal tract that could lead to damaging of the gastrointestinal wall and gut leakage, the translocation of gut metabolites into the bloodstream. Study team hypothesize that gut leakage initiates inflammatory processes underlying the further development of severe dengue, including features associated with plasma leakage.\n\nThis study aims to investigate intestinal barrier dysfunction (gut leakage) in dengue infection by detecting the translocation of gut-derived bacteria and their products (Lipopolysaccharides, LPS binding protein, sCD14, I-Fatty Acid Binding Protein) into the bloodstream. Study team will recruit hospitalized adult dengue patients (18 years and older) presenting with warning signs or severe disease in a tertiary care public hospital at Chattogram, Bangladesh. Circulating biomarkers indicative of gut permeability and microbial translocation will be measured to assess their presence and association with disease severity.\n\nAbdominal ultrasonography will be performed to characterize gastrointestinal alterations and determine their correlation with biochemical markers of gut leakage and clinical severity. In addition, study team will analyze the gut bacteriome from stool\u002F rectal swab of these patients to explore whether dengue infection induces compositional changes in intestinal microbiota and whether such alterations are linked to gut leakage or disease progression.",[163,164,165,166,167,168],"Dengue","Dengue Hemorrhagic Fever","Intestinal Disease","Ascites","Dengue With Warning Signs","Gut Microbiome","2026-08-03",{"date":171,"type":41},"2026-08-06",{"date":96,"type":41},{"date":174,"type":23},"2028-01-31",{"name":47,"class":48},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":17,"sex":18,"minAge":184,"maxAge":135,"enrollmentInfo":185,"targetDuration":4,"studyType":61,"phases":187,"briefSummary":188,"conditions":189,"keywords":192,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},"100607908","phase-4-r21mm-dosing-presentations-and-preservatives-100607908","NCT07194668","R21\u002FMM Dosing, Presentations, and Preservatives","Immunogenicity of a Fractional Adult Dose of the Malaria Vaccine R21\u002FMatrix-M - A Noninferiority Trial","VAC100","Inclusion Criteria:\n\n* Residence in a study village for the study period, i.e. 12 months.\n* Age 14 years to 60 years.\n* Written informed consent\u002Fassent provided by participants (or a parent\u002Fguardian in case the participant is under 18 years old).\n\nExclusion Criteria:\n\n* Pregnancy, plan to get pregnant within one month of vaccination, or breastfeeding.\n* Acute illness requiring intervention.\n* A history of an adverse reaction to study vaccine.\n* Prior receipt of any other malaria vaccine.\n* Enrolment in another intervention trial in the last month.\n* Planned enrolment in another intervention trial in the coming 12 months.\n* Regular use of Immunomodulating drugs e.g, Steroid, Methotrexate, Immunotherapy etc. in the past month and\u002For planned for the coming 12 months.","14 Years",{"count":186,"type":23},375,[63],"This is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21\u002FMatrix-M malaria vaccine is as effective as the full dose in children and adults. The results will help optimize vaccine usage and improve malaria prevention strategies.\n\nAll participants will receive the same number of injections and will be randomly assigned to receive one of the followings:\n\n* Group 1: Adults and adolescents receiving the standard adult vaccine dose: 10μg R21\u002F50μg Matrix-M (n=125).\n* Group 2: Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21\u002F50μg Matrix-M: 10 dose vials with adaptor Preservative Free (n=125)\n* Group 3: Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21\u002F50μg Matrix-M: 10 dose vials with 2PE Preservative (n=125)\n\nClinical procedure for participants:\n\n* Standardized symptom questionnaire\n* Physical examination:\n\nWeight, height, pulse, blood pressure, respiratory rate, tympanic temperature. Spleen and liver size will be recorded if palpable. Pregnancy test (for female of child bearing potential)\n\n* Venous blood collection (Pre-vaccination) 3mL\n* Vaccination",[190,142,191],"Plasmodium Falciparum Malaria","Vaccine Reaction",[190,193],"Malaria Vaccine",{"date":143,"type":41},{"date":196,"type":23},"2026-08-15",{"date":198,"type":23},"2026-12-31",{"name":47,"class":48},2,{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":208,"enrollmentInfo":209,"targetDuration":211,"studyType":25,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},"100452271","the-oxford-risk-factors-and-non-invasive-imaging-study-100452271","NCT05169333","The Oxford Risk Factors And Non-Invasive Imaging Study","ORFAN","Inclusion Criteria:\n\nInclusion Criteria for study Arms 1, 2 and 3:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged 18 -99 years.\n\nInclusion Criteria for study Arm 4:\n\n• Male or Female, aged 18 -99 years.\n\nExclusion Criteria:\n\nExclusion Criteria for Study Arms 1, 2 and 3:\n\n* Unable or unwilling to consent\n* Active cancer\n\nExclusion Criteria for Study Arm 4:\n\n* Participation in Study Arms 1, 2 or 3\n* Existing opt-out from use of data for research purposes","99 Years",{"count":210,"type":23},250000,"15 Years","ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.",[214,215],"Cardiovascular Diseases","Cardiovascular Risk Factors","2026-07-30",{"date":218,"type":41},"2026-07-31",{"date":220,"type":41},"2016-02-23",{"date":222,"type":23},"2030-02",{"name":47,"class":48},45,{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":18,"minAge":233,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":61,"phases":236,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},"100416617","phase-4-southeast-asia-dose-optimization-of-tafenoquine-100416617","NCT04704999","Southeast Asia Dose Optimization of Tafenoquine","Optimizing the Dose of Tafenoquine for the Radical Cure of Plasmodium Vivax Malaria in Southeast Asia","SEADOT","Inclusion Criteria:\n\n* Patients with symptomatic P. vivax mono-infection as diagnosed by microscopy\n* Fever or history of fever in the previous 7 days\n* Quantitative G6PD activity ≥70% of the population median\n* Weight \\>10 kg and ≥2 years old\n* Ability to understand the study instructions and provide written informed consent.\n* Willing to be followed for 4 months\n\nExclusion Criteria:\n\n* Pregnancy\n* Lactation\n* Hb \\\u003C 8 g\u002FdL\n* Severe malaria\n* Blood transfusion in the last 4 months\n* History of allergic response to an 8-aminoquinoline or the nationally recommended schizonticide (e.g., chloroquine, artemether-lumefantrine)\n* Any previous history of a haemolytic event Presence of any condition which in the judgement of the investigator would place the patient at undue risk or interfere with the results of the study (e.g. chronic disease, medications that potentiate or inhibit CYP2D6 or CYP2C8 isoenzyme function)","2 Years",{"count":235,"type":23},820,[63],"Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the substantial advantage of single dosing as compared to a 14-day course of primaquine to achieve radical cure. The recommended tafenoquine dose is 300 mg, which was shown to be significantly worse in radical curative efficacy to a total primaquine dose of 3.5 mg\u002Fkg in Southeast Asia. The cure rate of tafenoquine 300 mg in Southeast Asian study sites was only 74%. The comparator 3.5 mg\u002Fkg total primaquine dose is the standard and most commonly used dose globally, but in Southeast Asia and the Western Pacific, higher doses of primaquine are needed for radical cure. This study aims to determine the optimal dose of tafenoquine in Southeast Asia.\n\nAddendum for Indonesia: The INSPECTOR trial results showed that tafenoquine 300mg was not efficacious for radical cure (79% probability for recurrence after treatment). The comparator arm, low-dose primaquine 3.5mg\u002Fkg divided equally over 14 days, showed a 48% probability of recurrence after treatment). The standard of care for radical cure in Indonesia is high-dose primaquine 7mg\u002Fkg divided in 7 daily doses).",[239],"Plasmodium Vivax Malaria",[241,242,243,244,245,246,247,248,249],"Plasmodium vivax","Relapse","8-aminoquinoline","Tafenoquine","Radical cure","Drug efficacy","Adults","Pediatrics","Primaquine","2026-07-27",{"date":252,"type":41},"2026-07-29",{"date":254,"type":41},"2024-07-22",{"date":256,"type":23},"2028-02-07",{"name":47,"class":48},6,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":17,"sex":265,"minAge":19,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":49},"100629105","placental-biology-in-health-and-disease-100629105","NCT07470320","Placental Biology in Health and Disease","Inclusion Criteria:\n\n* Female, aged 18 years or above\n* Willing and able to give informed consent for participation in the study\n* Able to read and understand written and spoken English to comprehend study materials and give informed consent\n* Non-pregnant women in good general health OR pregnant women who fall into one of the following:\n\n  * Healthy pregnancy\n  * Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria\n  * Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy\n  * Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities\n  * Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies\n\nExclusion Criteria:\n\n* Non-pregnant participants with active health conditions that could confound study outcomes\n* Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies","FEMALE",{"count":267,"type":23},360,"Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.\n\nA major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.\n\nThis single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and\u002For uterine vein blood samples.\n\nThrough examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.",[270,271,272,273,274,275],"Pre-eclampsia","Gestational Diabetes Mellitus (GDM)","Fetal Growth Restriction (FGR)","Pregnancy Induced Hypertension (PIH)","Placenta","Pregnancy","2026-07-21",{"date":278,"type":41},"2026-07-23",{"date":280,"type":41},"2025-12-16",{"date":282,"type":23},"2030-05-31",{"name":47,"class":48},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":49},"100609485","neuropsychiatric-outcomes-and-disrupted-sleep-following-acquired-brain-injury-100609485","NCT07215195","Neuropsychiatric Outcomes and Disrupted Sleep Following Acquired Brain Injury","NODS","Inclusion Criteria:\n\n* Willing and able to give informed consent for participation in the study.\n* Aged 18 years or above.\n* At least one week, but less than 12 months post-injury\n* Clinical diagnosis of acquired brain injury (stroke, haemorrhage or traumatic).\n* Participants with Traumatic Brain Injury will have a Mild (probable) or Moderate-severe (definite) brain injury according to the Mayo classification\n* Participants must be willing to consent to us contacting their general practitioner (GP) or direct care team if we have concerns about their mental health\n\nExclusion Criteria:\n\n* Brain injury not caused by trauma, haemorrhage or stroke\n* Previous brain injury.\n* Other relevant neurological conditions which could affect outcome measures (e.g., Parkinson's or Alzheimer's disease)\n* No stable and suitable place to sleep",{"count":292,"type":23},150,"The two most common causes of brain injury are stroke and trauma. Both sleep and mental health problems are common after brain injury; we will investigate whether there is a relationship between poor sleep quality and worse mental health in this group. We will also follow patients up, at approximately three-monthly intervals until one year after injury, to see how sleep and mental health symptoms change over time and with recovery.\n\nWe will assess sleep in detail using questionnaires, a sleep monitor worn on the wrist, a portable brain activity sensor, and a sleep mat. We will assess mental health (neuropsychiatric) symptoms using questionnaires.\n\nParticipants will be asked to complete these assessments at baseline and at approximately 3-monthly intervals until they reach 12 months post-injury.\n\nThis data will allow us to explore the types of sleep disruption seen after brain injury and examine the association between sleep and mental health symptoms.",[295],"Acquired Brain Injury (Including Stroke)",[297,298,299,300,301,302],"stroke","traumatic brain injury","neuropsychiatric disorder","movement","sleep","brain injury",{"date":278,"type":41},{"date":305,"type":41},"2025-10-10",{"date":307,"type":23},"2027-11-30",{"name":47,"class":48},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":317,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":49},"100579206","surveillance-of-amr-in-drc-100579206","NCT06821282","Surveillance of AMR in DRC","Surveillance of Antimicrobial Resistance in Semirural Kinshasa, Democratic Republic of Congo: a Feasibility Study","SARKIN","Patients older than six months who present with a clinically suspected bloodstream infection upon admission to the hospital, or who have been hospitalized for less than 48 hours, and provide written consent (or consent from their caregiver\u002Flegal guardian) to participate will be included. Patients with a significant history of healthcare exposure and those with any contraindications for phlebotomy as determined by the clinician's judgment, will be excluded.","6 Months",{"count":319,"type":23},210,"This study addresses knowledge gaps regarding antimicrobial resistance (AMR) in sub-Saharan Africa, focusing on evaluating the feasibility of AMR surveillance and enhancing local research capacity. Conducted at a general referral hospital in semirural Kinshasa, DRC, the study will investigate bacterial infections, their resistance profiles, and related risk factors, including co-infections such as malaria.",[322],"Bacteremia",[324,325,142,326,327],"Antimicrobial resistance (AMR)","Surveillance","Africa","Democratic Republic of Congo",{"date":278,"type":41},{"date":330,"type":41},"2024-11-11",{"date":332,"type":23},"2026-09-30",{"name":47,"class":48},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":61,"phases":343,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":49},"100646327","repeated-real-time-biofeedback-with-7-tesla-mri-for-treatment-of-depression-100646327","NCT07694076","Repeated Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression","Inclusion Criteria:\n\n* Male or female aged 18-65 years;\n* Meets DSM-5 criteria for major depressive disorder (MDD) as determined by the Structured Clinical Interview for DSM-5 Axis Disorders (SCID) or the Mini International Neuropsychiatric Interview (MINI); with a current major depressive episode.\n* Participants must have a level of understanding of the English language sufficient to agree to all tests and examinations required by the study and must be able to participate fully in the informed consent process.\n\nExclusion Criteria:\n\n* Current or history of schizophrenia or other psychotic disorder, neurodevelopmental disorder, neurocognitive disorder or cognitive impairment\n* Active substance use disorder within the past 1 year;\n* Any unstable medical illnesses;\n* Women who are pregnant;\n* Any contraindications to MRI\n* Antidepressant medication initiated within 2 weeks of the Baseline Assessment and concomitant use of any other medication with central nervous system activity during active participation;\n* Active suicidal intent or plan.","65 Years",{"count":342,"type":23},60,[111],"Previous work demonstrated that individuals are able to self-regulate their ventral tegmental area (VTA) activity using real-time biofeedback. The current study expands this approach to a larger sample with repeated training sessions to more robustly characterize the effects of VTA modulation. The study will assess change in mood and motivation-related measures, as well as neural activity and connectivity changes.",[346],"Major Depressive Disorder (MDD)",[348,349,350,351,352],"Brain imaging","Biofeedback","7-Tesla MRI","Depression","Dopamine","2026-07-06",{"date":355,"type":41},"2026-07-09",{"date":357,"type":23},"2026-06",{"date":359,"type":23},"2033-06",{"name":47,"class":48},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":61,"phases":372,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":100},"100597164","phase-2-combination-vaccination-and-broadly-neutralising-antibody-therapy-in-hiv-100597164","NCT07054931","Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV","AbVax: Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV to Induce a Protective T-cell 'Vaccinal Effect' - a Randomised Phase II Clinical Trial","AbVax","Inclusion Criteria:\n\n* PWH aged ≥18 to ≤64 years old at screening\n\n  * Able to give informed written consent including consent to long-term follow-up\n  * Willing and able to comply with visit schedule and provide blood sampling\n  * Willing to consent to their HIV care team being informed of their participation and sharing relevant clinical information\n  * Stable on oral ART with suppressed undetectable HIV pVL 'target not detected' (TND) using local assays for ≥ 1 years (a single viral load measurement \\>50 but \\\u003C500 copies\u002Fml during this time period is allowable)\n  * No evidence of viral insensitivity to GS-2872 based on proviral sequencing\n  * No significant co-morbidities according to the investigator's opinion\n  * Nadir CD4 \\>200 cells\u002Fµl unless treatment commenced during documented acute seroconversion\n  * Current CD4 count \\>500 cells\u002Fµl or CD4:CD8 ratio \\>1.0\n  * On integrase inhibitor (INSTI) or boosted protease inhibitor (bPI) based regimen at time of randomisation. If previously on non-nucleoside reverse transcriptase inhibitor (NNRTI) must have switched at least 4 weeks prior to randomisation\n  * Adequate haemoglobin (Hb ≥12 g\u002FdL for males, ≥11 g\u002FdL for females)\n  * Weight ≥ 50kg\n  * Has received at least 3 doses of vaccination against coronavirus (COVID-19), at least 4 weeks prior to randomisation\n  * Has received current seasonal vaccination against Influenza\\*\n  * People of childbearing potential\\*\\* must agree to use hormonal contraception, intrauterine device, intrauterine hormone-releasing system, or otherwise practice complete abstinence\\*\\*\\* from at least two weeks before the first Investigational Medicinal Product (IMP) administration, for at least 20 months after the last IMP administration, and until undetectable viral load on ART\n  * All participants must agree to take precautions to prevent onward transmission of HIV (such as condoms or PrEP) whilst they are off ART and\u002For have a detectable viral load \\* Applicable during Influenza season (September-April inclusive). \\*\\*Individuals capable of becoming pregnant are defined as those who are fertile, with childbearing reproductive organs, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Permanent sterilisation of the participant's sole partner (e.g. vasectomy) is also accepted.\n\nA postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in those not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n\n\\*\\*\\*Complete abstinence (defined as refraining from heterosexual intercourse) must be in line with the preferred and usual lifestyle of the participant. Barrier contraception, periodic abstinence (e.g. calendar, ovulation, symptothermal, post ovulation methods), withdrawal and progestogen-only oral hormonal contraception where inhibition of ovulation is not the primary mode of action are not acceptable methods of contraception.\n\nExclusion Criteria:\n\n* • Previous ischaemic heart disease (ST or non-ST myocardial infarction, Q3-risk \\>20, stable angina, unstable angina, stroke)\n\n  * Any current or past history of malignancy, excluding squamous cell skin cancers\n  * Concurrent opportunistic infection or other co-morbidity likely to occur during the trial e.g.\n\nmalabsorption syndromes, autoimmune disease\n\n* Any contraindication to receipt of BHIVA recommended combination antiretrovirals\n* Current treatment with injectable ART\n* HTLV-1 co-infection\n* Any evidence of major antiretroviral resistance mutations\n* Evidence of HBV infection requiring treatment (HBsAg+, or HBcAb+ without HBsAb+)\n* Evidence of HCV infection (HCVAg+ and\u002For HCV RNA detected)\n* Individuals at high risk from severe Covid-19 disease who may be defined in accordance with NHSE guidance as vulnerable and shielded (as per the view of participant's physician)\n* Current or planned systemic immunosuppressive therapy (inhaled and topical corticosteroids are allowed)\n* Participation in another research study involving receipt of an investigational medicinal product (IMP) in the 3 months preceding enrolment or 5 half-lives of the investigational medicinal product, whichever is longer, or planned participation during the study period (concurrent observational studies are allowed)\n* History of anaphylaxis or severe adverse reaction to antibody infusions, or hypersensitivity to GS-2872 or GS-5423 or to any constituent products or excipients thereof\n* History of anaphylaxis or severe adverse reaction to any previous vaccine\n* A history of thrombosis with thrombocytopaenia syndrome (TTS) following vaccination with any adenoviral vector vaccines\n* A history of anti-phospholipid syndrome\n* A history of heparin-induced thrombocytopenia\n* A history of cerebral venous sinus thrombosis\n* Any history of other bleeding or clotting disorders of clinical significance according to the investigator's discretion\n* Known anti-PF4 antibody positivity\n* Treatment with IV immunoglobulin or other monoclonal antibody treatments planned during the duration of the trial\n* Clinically significant abnormal blood test results at screening including\n\n  1. Moderate to severe hepatic impairment as defined by significant liver impairment with evidence of advanced fibrosis or cirrhosis with decompensation\n  2. ALT \\>5 x ULN\n  3. eGFR \\\u003C601\n  4. uPCR \\>30 mg\u002Fmmol\n  5. INR \\>1.5\n* Evidence of organ dysfunction or any clinically significant deviation from normal in medical history, physical examination and\u002For vital signs that the investigator believes is a preclusion from enrolment into the study\n* Active alcohol or substance use that, in the investigator's opinion, will prevent adequate adherence with study requirements\n* Insufficient venous access that will allow scheduled blood draws as per protocol\n* Concern regarding likelihood of participant not taking precautions to prevent HIV transmission during treatment interruption period\n* Pregnancy, lactation or intending to become pregnant\n* Participants unable to be followed closely for geographic, social or psychological reasons\n* Participants unable to adequately understand written or verbal English to appropriately consent to the study","64 Years",{"count":371,"type":23},48,[373],"PHASE2","There is no cure for HIV infection. Antiretroviral therapy (ART) is widely available but requires daily, life-long intake. This can cause issues around side-effects, resistance, adherence and stigma. A new therapy, broadly neutralising antibodies, (bNAbs), may work as well as ART and may last longer - one dose can last six months. bNAbs appear to first target HIV viruses, then drive a protective immune response conferring long-term control, called the vaccinal effect. AbVax is a clinical trial to understand this effect and how to enhance it to give the strongest possible long-term protection for people living with HIV (PWH). The investigators are studying whether a combination of vaccines that attack HIV, a short period of treatment interruption induced viraemia (TIIV - stopping ART for a few weeks to allow a small amount of virus to return to the bloodstream) and bNABs will produce the most sustained immune protection.",[376],"HIV",[378,379,380],"vaccination","broadly neutralising antibodies","HIV treatment",{"date":382,"type":41},"2026-07-07",{"date":384,"type":41},"2025-09-05",{"date":386,"type":23},"2028-06-30",{"name":47,"class":48},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":61,"phases":397,"briefSummary":398,"conditions":399,"keywords":402,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":49},"100631879","hope-groups-parenting-and-mental-health-among-refugees-in-the-middle-east-100631879","NCT07506421","Hope Groups: Parenting and Mental Health Among Refugees in the Middle East","Hope Groups: A Small-Scale Randomised Controlled Trial Of Psychosocial And Parenting Support Groups For Palestinian Caregivers Affected By War In The Middle East","Inclusion Criteria:\n\n* Participant is living in one of our partner refugee camps.\n* Participant is a parent\u002Fcaregiver for one or more child (of any age).\n* Participant is over the age of 18.\n* Participant has high, medium, or low literacy. (Note: This is in order to use our Hope Groups programme guide. Our team is concerned that individuals with no literacy would need more audio files, rather than just a text-driven participant guide. If Hope Groups demonstrate effectiveness in this pilot, investigators will have focus groups with low-literacy participants, to create a future version which is suitable for people of all literacy backgrounds.)\n* Participant consents to participate in the study.",{"count":396,"type":23},490,[111],"This research is testing if 'Hope Groups' -- a psychosocial, mental health, parenting strengthening, and violence prevention support group program -- work to help Palestinian caregivers displaced by war.",[400,401],"Mental Health","Violence Against Children",[403,404,405,401,406],"War","Displacement","Parenting","Refugee","2026-06-15",{"date":409,"type":41},"2026-06-17",{"date":411,"type":41},"2025-02-05",{"date":147,"type":23},{"name":47,"class":48},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":421,"maxAge":19,"enrollmentInfo":422,"targetDuration":4,"studyType":61,"phases":424,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":49},"100642354","vrehab-sma-phase-12-100642354","NCT07578454","VRehab-SMA Phase 1.2","Virtual Targeted Rehabilitation for Patients With Spinal Muscular Atrophy: Phase 1.2: Proof-of-concept","Cohort 1 Inclusion Criteria:\n\n* Person with SMA\n\n  * A person living with genetically confirmed SMA aged from 12-18 years\n  * A good understanding of English or someone who can provide a good understanding of English for me to complete the survey\n  * A young person living with SMA from 12-15 years of age and who's caregiver\u002Flegal guardian gives consent\n  * A young person living with SMA from 16-18 years of age who provide their own consent\n\nCaregiver\u002F Legal Guardian\n\n* A caregiver (legal guardian) of child\u002Fyoung person living with SMA aged from 6-18 years old\n* A good understanding of English or someone who can provide a good understanding of English for me to complete the survey\n\nExclusion Criteria: No exclusion criteria for Cohort 1, other than meeting the inclusion criteria\n\nCohort 2 Inclusion Criteria:\n\nParticipant with SMA aged 6-10 years\n\n* Genetically confirmed SMA\n* A comprehensive understanding of English\n* Treated with any disease-modifying therapy post-symptomatically\n* Number of SMN2 copies available\n* Functional status available\n* Age: Participants between 6-10 years at Visit 1 (inclusion)\n* Parent(s)\u002Flegal guardian(s)\u002Fcaregiver(s) able to provide written informed consent and child able to provide assent prior to participation in the study\n\nParticipant with SMA aged 11-15 years\n\n* Genetically confirmed SMA\n* A comprehensive understanding of English\n* Treated with any disease-modifying therapy post-symptomatically\n* Number of SMN2 copies available\n* Functional status available\n* Age: Participants between 11-15 years at Visit 1 (inclusion)\n* Parent(s)\u002Flegal guardian(s)\u002Fcaregiver(s) able to provide written informed consent and child able to provide assent prior to participation in the study\n\nParticipant with SMA aged 16-18 years\n\n* Genetically confirmed SMA\n* A comprehensive understanding of English\n* Treated with any disease-modifying therapy post-symptomatically\n* Number of SMN2 copies available\n* Functional status available\n* Age: Participants between 16-18 years at Visit 1 (inclusion)\n* Able to provide written informed consent\n\nExclusion Criteria:\n\nAny acute or chronic condition which, according to the investigator, significantly interferes with the use of the device (example: Upper limbs injuries interfering with technology, skin conditions preventing the use of electrodes, etc)","6 Years",{"count":423,"type":23},12,[111],"Spinal muscular atrophy is a genetic disorder characterized by progressive muscle weakness, severely impacting patients' motor abilities. Several disease modifying therapies have been developed to treat Spinal muscular atrophy which have led to new disease trajectories . According to standard of care guidelines, exercise programs should be designed and monitored by a physical therapist and should include exercises to improve daily life activities. Exercises should be adapted to each patient and can be prescribed with an optimal frequency in various ways. However, of patients with Spinal muscular atrophy, only 20% reported access to endurance exercises and only 6% to mixed exercises. This incompliance to standard of care guidelines is due to manpower limitation and difficulties in engaging with young and sometimes highly disabled children. Our group has been pioneering in developing the UK at-home individualised rehabilitation program. To address this challenge, the Investigators propose the development of an innovative, virtual targeted rehabilitation platform specifically designed for young patients with Spinal muscular atrophy. This technology aims to provide a patient-centric, at-home rehabilitation solution, enabling parents\u002Fcaregivers to facilitate daily exercises in a more accessible and enjoyable manner. This technology would constitute the first of its kind in Spinal muscular atrophy field, involving the integration of augmented electromyography signals and soft robotic haptic devices into a gamified virtual reality environment. By increasing the frequency and quality of exercise interventions at home, this technology has the potential to significantly address the critical unmet need for consistent rehabilitation. This technology will also serve as a clinical outcome measure for continuous home-based assessments of weaker and less functional population in place of hospital-based assessments.",[427],"Spinal Muscular Atrophy (SMA)",[429],"Spinal Muscular Atrophy","2026-06-09",{"date":432,"type":41},"2026-06-11",{"date":434,"type":41},"2026-05-27",{"date":436,"type":23},"2027-04",{"name":47,"class":48},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":17,"sex":446,"minAge":447,"maxAge":448,"enrollmentInfo":449,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":450,"conditions":451,"keywords":453,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":49},"100625468","a-remote-study-using-technology-to-assess-outcomes-in-dmd-100625468","NCT07423026","A Remote Study Using Technology to Assess Outcomes in DMD","TODDLER Study: Transforming Outcomes in Duchenne Muscular Dystrophy Using DigitaL Endpoints Remotely","TODDLER","Inclusion Criteria:\n\nParticipant with DMD:\n\n* Male\n* Aged 1-3 years old\n* Ambulant (walking 10m independently)\n* Genetically confirmed diagnosis of DMD\n* Parent(s)\u002Flegal guardian(s) able and willing to provide written informed consent for the child to participate in the study\n* Parent(s)\u002Flegal guardian(s) able and willing to participate in the study\n\nParent\u002Flegal guardian of participant with DMD:\n\n* Aged 18 years or more\n* Legal carer of the patient diagnosed with DMD\n* Willingness to follow study procedures and assist with remote assessments, as assessed by the research team\n* Willingness to sign the consent form\n* Ability to understand all the information with regards to the study, as assessed by the research team\n\nHealthy Control participant:\n\n* Male\n* Aged 1-3 years old\n* Ambulant (walking 10m independently)\n* Parent(s)\u002Flegal guardian\n\nExclusion Criteria:\n\nParticipant with DMD:\n\n* Limb surgery\u002Ftrauma (within 6 months)\n* Significant comorbid chronic or acute conditions affecting motor function (within 3 weeks)\n* Prematurity (born \\\u003C37 weeks' gestation)\n* Oral corticosteroids to treat DMD (before enrolment)\n* Enrolment in therapeutic clinical trials\n* Any comorbidity which could limit their ability to complete the study assessments (according to the investigator's clinical judgement)\n\nHealthy Control participant:\n\n* Limb surgery\u002Ftrauma (within 6 months)\n* Significant comorbid chronic condition affecting motor function\n* Significant acute condition affecting motor function (within 3weeks of enrolment)\n* Prematurity (born \\\u003C37 weeks' gestation)\n* Neurodevelopmental concerns or delay in acquisition of WHO developmental milestones.\n* Any comorbidity which could limit their ability to complete the study assessments (according to the investigator's clinical judgement).","MALE","1 Year","3 Years",{"count":342,"type":23},"Every year, 100 boys are born in the UK with a rare muscle disease called Duchenne muscular dystrophy. These boys cannot make an important muscle protein called dystrophin. They become weaker as they get older and lose the ability to walk as teenagers. This is a life-limiting condition. There is no cure, but medicines are being made that could help these boys make dystrophin. These medicines are most likely to work best in toddlers, before their muscles become damaged.\n\nThere is no way of testing these medicines in children under four. In older children, it is possible to measure how well and how quickly a child can do movements like sitting up, standing up, and running. Unfortunately, these tests are not suitable for toddlers as they often struggle to listen and do what they are asked to do. Tiredness and mood can also affect their scores. Luckily, there is a new way of testing how well children move. They can wear special watch-like devices on their ankles that record information about their steps as they go about their normal lives. This is a good way of testing how well a child walks. It is now used to test medicines in children over four years old. Our aim is to test whether this device works well in children under four.\n\nThis study will invite 30 boys with DMD (and their parent\u002Fcaregiver) and 30 boys without DMD aged 1-3 years old from across the country to join the study. There are no hospital visits. Children will receive the watch-like devices to wear for three blocks of 28-days over six months during their normal daily activities. At the start and end of the study, a physiotherapist will visit the homes of boys with DMD. They will check their movements using other tests. The investigators will find out 1) if young boys are happy to wear the device, 2) how it compares to other tests, and 3) if it can detect changes in walking ability.\n\nThis study could give us a way to test medicines in younger children. Wearable devices could cut down the travel and stress of tests for boys and their families. Children with learning or behavioural difficulties, and children living far from research centres could now also take part in studies of new medicines. This study could bring us a step closer to treating this life-limiting disease.",[452],"Duchenne Muscular Dystrophy (DMD)",[454,455,456],"DMD","Devices","children",{"date":458,"type":41},"2026-06-10",{"date":460,"type":23},"2026-06-24",{"date":462,"type":23},"2028-07-01",{"name":47,"class":48},{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":482,"leadSponsor":483,"locationsCount":4},"100639246","inflammation-digital-biomarkers-validation-study-100639246","NCT07594054","Inflammation Digital Biomarkers Validation Study","IDBV: Inflammation Digital Biomarker Validation Study","IDBV","Inclusion Criteria:\n\nPreviously consented to take part in the HPOS study and have agreed to be contacted for future ethically approved studies.\n\nAdults with psoriasis with no diagnosis of PsA.\n\nHave a compatible smartphone\n\nHave a good command of local language\n\nExclusion Criteria:\n\nParticipants not consented into the HPOS study\n\nDo not have use of a compatible smartphone\n\nAre not willing to use the smartphone app.\n\nAdults with a pre-existing diagnosis of PsA",{"count":473,"type":23},3458,"HIPPOCRATES is an Innovative Medicines Initiative (IMI) funded EU Consortium established to address key unmet clinical needs in psoriatic disease. As part of the project, the HIPPOCRATES Prospective Observational Study (HPOS) is a study of patients with psoriasis which is recruiting across Europe. The study is led by a research team at University of Oxford and supported by a team at University College Dublin. This current study aims to identify people with psoriasis who are at risk of developing psoriatic arthritis. Up to one-third of patients with psoriasis will develop a related arthritis causing inflammation in the joints and tendons. The investigators want to identify which patients will develop arthritis with the long-term and ambitious aim of trying to prevent the development of arthritis before it occurs. The HPOS study is currently recruiting\u002Fapproaching adults with psoriasis and asking study participants to complete questionnaires every 6 months via a dedicated study website. The questionnaires include a 'screening questionnaire' to try to identify arthritis.\n\nAdults with psoriasis but without a pre-existing diagnosis of PsA are currently being recruited via clinics, national and international patient support organisations including those under the umbrella of EUROPSO, and media campaigns. Participants are recruited across Europe in the following countries: UK, Ireland, Italy, France, Spain, Denmark, Germany, Belgium, Netherlands, Sweden, Portugal, Greece, Norway, Switzerland, Poland and Romania. The University of Oxford is the sponsor for the study across all countries, but local regulations will be followed, and local ethical approval has been sought for each different country. Data is requested from participants every 6 months and they will be prompted by email.\n\nLikewise, the iPROLEPSIS consortium is a Horizon Europe funded consortium investigating digital biomarkers in PsA. In 2024, the consortium launched a study recruiting 600 patients with PsA across 4 counties, utilising digital biomarkers to identify disease flares. This includes the use of smartwatches, a mobile phone app and active video tests. This will allow us to develop algorithms to identify active disease.\n\nSimilar approaches are proposed for a study called the Inflammation Digital Biomarkers Study (IDBV) which will try to identify the onset of PsA in people living with psoriasis. Patients in HPOS who have given consent to be contacted about additional studies, will be offered the opportunity to join this study. They will complete an additional consent form and will download the miPROLEPSIS lite app to their mobile phone.\n\nThe Study app will passively collect data from the user's phone; participants do not need to perform any specific tasks apart from some initial configuration steps like logging in and connecting their wearables (Connecting a wearable is optional).\n\nThe investigators intend to run IDBV as a sub-study in HPOS and invite participants enrolled into the HPOS study who do not have a diagnosis of PsA.",[476,477],"Psoriatic Arthritis","Psoriasis (PsO)","2026-05-20",{"date":480,"type":41},"2026-05-22",{"date":357,"type":23},{"date":125,"type":23},{"name":47,"class":48},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":265,"minAge":58,"maxAge":135,"enrollmentInfo":492,"targetDuration":4,"studyType":61,"phases":494,"briefSummary":495,"conditions":496,"keywords":501,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":49},"100641020","probiotic-intake-and-perimenopausal-psychological-assessments-100641020","NCT07590999","Probiotic Intake and Perimenopausal Psychological Assessments","The Effects of a Probiotic on Emotional Processing, Cognition, and the Gut Microbiome in Perimenopausal Women","PIPPA","Inclusion Criteria:\n\n* Female at birth\n* You are aged 45-60 years and in perimenopause (determined by changes in menstrual bleeding patterns (such as changes in cycle length of 7 days or longer in either direction from what is normal for you), AND vasomotor symptoms (e.g., hot flushes and sweats) AND mild to moderate mood or cognitive disturbances, or joint and muscle pain over the previous 12 months)\n* You are willing and able to give informed consent for participation in the study\n* You are sufficiently fluent in English to understand and complete tasks\n* You are at least 12 months post-natal\n* Willing to withhold from having grapefruit juice\n\nExclusion Criteria:\n\n* Currently receive or seek treatment for any mental health condition\n* Have a BMI \\>=30 OR \\\u003C=18.5\n* Have lost or gained more than 10% of body weight in a short period (e.g., 6 months), as this can affect mood and cognition\n* Currently using hormonal contraception or have used hormonal contraception in the last 6 months\n* Have had gender reassignment surgery or gender-affirming hormone therapy\n* Had a head injury causing concussion or unconsciousness in the past 6 months\n* Participated in other studies that may influence mood, cognition, or gut health in the last three months\n* Are currently diagnosed with and\u002For treated for psychiatric or neurological disorders\n* Are on perimenopausal hormone replacement therapy (HRT) (e.g., estrogen, progesterone, testosterone) or other hormone-modulating medications (e.g., GLP-1 agonists, thyroxine replacement), as these can impact mood and cognitive functions\n* Currently use statins or have used statins in the last 6 months, as these may impact mood and cognitive functions\n* Participated in any other study with the same tasks in the last year\n* Currently use medications that influence cognition or mood, such as antidepressants, anxiolytics, antipsychotics, stimulants, mood-stabilizers, or cognitive-enhancing drugs\n* Have chronic or severe gastrointestinal diseases (e.g., inflammatory bowel disease, Crohn's disease, celiac disease, or severe acid reflux; treatment with e.g., corticosteroids, antacids), as these conditions and treatments can affect the gut microbiota and immune responses differently from healthy individuals\n* Have a compromised immune system\n* Currently smoke, vape, or use any other nicotine products\n* Have a current diagnosis of cognitive impairment or neurodegenerative disorders (e.g., mild cognitive impairment, dementia), as these conditions could confound cognitive assessments.\n* Have severe medical conditions requiring ongoing medication that may independently affect cognition or mood (e.g., diabetes)\n* Currently or recently used antibiotics (last 3 months), as antibiotics may alter gut microbiota and interfere with probiotic effects\n* Currently or recently used probiotics or prebiotics or consumed fermented products (e.g., kimchi, kombucha, sauerkraut, kefir, etc.) on a regular basis (last 3 months), which might interfere with the study intervention\n* Have known allergies or intolerances to probiotics or components in the probiotic supplement.\n* Have substance abuse or dependence (e.g., alcohol, recreational drugs) that may affect mood and cognition.\n* Have Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (Long COVID)\n* Have had a hysterectomy\n* Are pregnant or lactating, as hormonal changes associated with these states could confound results.\n* Score of 20 or above on PHQ-9 depression questionnaire, indicating severe depression\n* Score of \\>1 on PHQ-9 suicidality item, indicating significant suicidality (as assessed by medical on-site professionals",{"count":493,"type":23},106,[111],"Recent evidence suggests multi-strain probiotics containing Lactobacillus rhamnosus and Bifidobacterium longum have been found to enhance emotional processing and reduce salience to negative cues in studies involving people with mood disorders, as well as improve cognitive functions, such as memory and concentration, in healthy participants. By administering computer-based tasks, questionnaires and checking biological measures (cortisol, immune markers, blood metabolites, gut microbiota) using blood and faecal samples, this experimental medicine study aims to investigate whether a probiotic supplement has an effect on emotional processing and cognition in perimenopausal women. We also aim to study changes in gut bacteria from stool samples before and after taking the supplement to see if any microbiome changes are associated with any effects in emotional processing, cognitive function, and biological markers.",[497,498,499,500],"Emotional Processing and Cognitive Function in Perimenopausal Women Experiencing Cognitive Perturbations","Perimenopause","Perimenopause-Related Depression","Perimenopausal Women",[502,503,504,505,506,507,508,509,510,511],"perimenopause","menopause","gut microbiome and perimenopause","cognition and perimenopause","emotional processing and perimenopause","mood and perimenopause","gut microbiome and cognition","probiotics","probiotic","gut microbiome","2026-05-12",{"date":514,"type":41},"2026-05-15",{"date":516,"type":41},"2025-11-12",{"date":518,"type":23},"2027-06-30",{"name":47,"class":48},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":528,"enrollmentInfo":529,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":531,"conditions":532,"keywords":533,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":49},"100634693","an-international-federated-model-for-wearable-derived-remote-longitudinal-motor-monitoring-in-young-children-with-spinal-muscular-atrophy-compared-with-healthy-controls-active-nbs-study-uk-100634693","NCT07543003","An International Federated Model for Wearable-derived Remote Longitudinal Motor Monitoring in Young Children With Spinal Muscular Atrophy Compared With Healthy Controls: Active-NBS Study (UK)","A Prospective, Longitudinal and Decentralised Study Investigating the Motor Development of Patients With Spinal Muscular Atrophy Identified by Newborn Screening Age 4 Years and Below: Active-NBS UK.","Active-NBS UK","Inclusion criteria (Test cohort):\n\n1. Genetically confirmed SMA and number of SMN2 copies available\n2. a. Patients identified by NBS and treated with disease modifying therapy (DMT)\n\n(2)a,i 4 copies or more of SMN2 and not treated with DMT\n\n(2)a,ii less than 4 copies of SMN2 and not treated with DMT\n\nor\n\n(2)b. Patients diagnosed due to a sibling or alternative means\n\n(2)b,i 4 copies or more of SMN2 and not treated with DMT\n\n(2)b,ii less than 4 copies of SMN2 and not treated with DMT\n\n(3)Patients between 4 months and below 4 years at baseline. Inclusion of patients can be before 4 months of age\n\n(4)Parent(s)\u002Flegal guardian(s) able to provide written informed consent prior to the patient's participation in the study\n\n(5)Male or female\n\nExclusion Criteria (Test cohort):\n\n1. Any acute or chronic condition which, according to the investigator, significantly interferes with the assessments and\u002For the motor evolution\n2. Currently enrolled in an experimental treatment study\n\nInclusion criteria (Control):\n\n1. Typically developing child\n2. Participant between 6 months and 4 years at inclusion\n3. Parent(s)\u002Flegal guardian(s) able to provide written informed consent prior to the participation in the study\n4. Male or female\n\nExclusion criteria (Control):\n\n(1)Any acute or chronic condition which, according to the investigator, significantly interferes with the assessments and\u002For the motor evolution","4 Years",{"count":530,"type":23},90,"Active-NBS is a study to evaluate the muscle development of patients with spinal muscular atrophy (SMA) who are diagnosed at birth.\n\nMedicines have become available in the last decade, and many patients are treated very early. Treatments are most effective if used before the patient develops symptoms. However, some patients may show symptoms by the time they receive treatment. This means that even with early diagnosis, they might still develop muscle weakness despite treatment. The investigators want to see when the movements of patients diagnosed at birth differ from normal development. This information will help identify the best time to give additional medicines currently being developed to support the muscle.\n\nThe investigators will track the progress of up to 60 patients over a maximum of 30 months using wearable technologies which are worn at home. The investigators aim to validate their outcomes for use in this age group. The wearable devices are called Syde and Motor Assessment of an Infant in a Jumpsuit (MAIJU).\n\nThey will be worn at regular intervals during the study and will not involve extra hospital visits for patients. The study will also recruit up to 30 healthy control participants and follow them for up to 30 months. This will help define normal development with use of the Syde device.\n\nActive-NBS will be conducted in the UK and internationally using a federated data model. Collaborative sites will collect harmonised data in accordance with the Active-NBS protocol, with data integration and oversight managed by the University of Oxford. International sites may contact the Oxford study team to establish collaboration.",[427],[534,535,536,537],"Spinal muscular atrophy","Newborn screening","Motricity","Development","2026-05-06",{"date":540,"type":41},"2026-05-11",{"date":542,"type":41},"2026-05-01",{"date":544,"type":23},"2029-07",{"name":47,"class":48},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":340,"enrollmentInfo":554,"targetDuration":4,"studyType":61,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":200},"100514058","blood-lipid-responses-to-diet-macronutrients-100514058","NCT05973539","Blood Lipid Responses to Diet Macronutrients","Investigating Blood Lipid Responses to Dietary Macronutrient Content","BoLD","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged ≥18 to ≤65 years\n* Body mass index (BMI) ≥19 to ≤35 kg\u002Fm2\n* No medical condition or relevant drug therapy that is known to affect the liver, adipose tissue, or cardiac metabolism.\n* Weight stable for the previous 3 months\n\nExclusion Criteria:\n\n* Aged \\\u003C18 or \\>65 years\n* BMI \\\u003C19 or \\>35 kg\u002Fm2\n* A blood haemoglobin \\\u003C135 mg\u002FdL for men and \\\u003C120 mg\u002FdL for women\n* Donated (or lost) ≥250 mL of blood in the previous two months\n* On a weight loss diet or decreased their body weight by \\>5% in the previous 3 months\n* Currently adhering to or have consumed in the previous 3 months a diet with a notably altered macro-nutrient content (e.g. high-fat - low-carbohydrate diet)\n* Have increased their body weight by \\>5% in the previous 3 months\n* Any metabolic condition or relevant drug therapy\n* Current smoker\n* History of alcoholism or a greater than recommended alcohol intake (\\>30 g of alcohol daily for men and \\>20 g of alcohol daily for women)\n* History of albumin allergy.\n* Pregnant or nursing mothers\n* History of severe claustrophobia",{"count":342,"type":23},[111],"The macronutrient composition of a diet (proportions of carbohydrates, fats and proteins) strongly influences the way the body stores and utilises substrates (e.g., fats and sugars), which in turn influences the risk of developing cardiometabolic diseases (e.g., coronary artery disease or insulin resistance). The optimal dietary composition to lower the risk of cardiometabolic disease is unknown.\n\nIn a randomized, parallel design, this study will investigate how the overconsumption of carbohydrates and fats affects blood lipid responses and liver metabolism in adults free from metabolic disease. By genotyping participants, the interaction between macronutrient content and an individual's genes on blood lipid responses and liver metabolism will be examined.",[558],"Nutritional and Metabolic Diseases",{"date":540,"type":41},{"date":561,"type":41},"2023-02-15",{"date":563,"type":23},"2028-01",{"name":47,"class":48},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":572,"targetDuration":573,"studyType":25,"phases":4,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":581,"locationsCount":49},"100486072","imaging-intravenous-iron-100486072","NCT05609318","Imaging Intravenous Iron","Study of Tissue Iron Uptake in Iron-Deficient Patients Receiving Intravenous Iron Replacement Therapy: A Prospective Observational Study (STUDY)","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Aged 18 years or above.\n* Anaemia (haemoglobin less than 120g\u002FL for women and less than 130g\u002FL for men) and\u002For confirmed iron deficiency (ferritin less than 100mcg\u002FL and\u002For transferrin saturation less than 20%).\n* Scheduled to receive intravenous iron for correction of iron deficiency.\n\nExclusion Criteria:\n\n* Any MRI incompatible implants (e.g. cardiac, neuro, ocular implants, surgical clips, aneurysm clips, shrapnel\u002Fbullets)\n* Pregnant or lactating participant\n* Acute decompensated heart failure\n* Unstable clinical status\n* Any other medical conditions which would influence the reliability of the study results determined by the investigators.\n* Any other contraindication to MRI to be confirmed by the qualified MRI operator, e.g. tattoos containing traces of metal.",{"count":423,"type":23},"6 Weeks","The aim of this study is to track where the iron goes in different tissues in the hours, days and weeks after an intravenous iron infusion. We will track iron in tissues using MRI relaxometry parameters R1\u002FR2\u002FR2\\* which are well established as accurate indicators of tissue iron content.",[576],"Iron-deficiency",{"date":540,"type":41},{"date":579,"type":41},"2022-10-29",{"date":198,"type":23},{"name":47,"class":48},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":61,"phases":591,"briefSummary":592,"conditions":593,"keywords":596,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":49},"100640749","closed-loop-tms-for-tremor-100640749","NCT07574164","Closed-loop TMS for Tremor","Transcranial Magnetic Stimulation for the Treatment of Tremo","Inclusion Criteria:\n\n* having either essential tremor or Parkinson's disease\n\nExclusion Criteria:\n\n* contraindications to brain stimulation",{"count":590,"type":23},20,[111],"This study investigates the potential of phase-locked transcranial magnetic stimulation (TMS) as a non-invasive intervention for tremor in patients with Essential Tremor (ET) and Parkinson's Disease (PD). Tremor is a prevalent symptom that significantly impacts physical function and social participation. ET affects approximately 1% of the global population and worsens with age, while PD tremor is often less responsive to conventional dopaminergic therapy. Current treatments, including oral medications (propranolol, primidone), anticholinergics, and deep brain stimulation (DBS), are either limited by efficacy, side effects, or invasiveness. These challenges highlight the need for alternative, less invasive therapeutic options.\n\nThe rationale for the study is based on the principle of phase-dependent neural modulation. Just as a swing's amplitude can be increased or decreased depending on when it is pushed, neural oscillations underlying tremor can theoretically be suppressed by precisely timed stimulation. Previous studies have shown that TMS over the motor cortex at tremor frequency (\\~5 Hz) produces modest improvements in PD rest tremor. This study aims to enhance these effects by targeting amplitude-suppressing phases in the tremor cycle, potentially leading to greater and cumulative tremor reduction.\n\nThe study has two components:\n\nStudy 1 (Primary Objective): Determine whether phase-locked TMS can acutely reduce tremor. Participants (20 ET, 20 PD) will undergo two visits where tremor is recorded via inertial measurement units (IMUs) and surface EMG. TMS will be delivered over the motor cortex at or below active motor threshold, synchronized to the participant's tremor phase. The primary outcome is the change in tremor power during stimulation compared to no stimulation, measured objectively via IMU signals.\n\nStudy 2 (Secondary Objective): Examine whether stimulation at the maximal tremor-suppressing phase, identified in Study 1, produces a larger reduction in tremor amplitude than stimulation at the minimal suppressing phase or sham stimulation. This will involve three additional sessions per participant, randomized for order, with outcomes assessed via IMU tremor power and participant-reported measures including the Quality of Life in Essential Tremor Questionnaire (QUEST), TETRAS, and Unified Parkinson's Disease Rating Scale (UPDRS).\n\nStudy Design and Procedures: The design is a within-subject crossover. Participants may withhold tremor medications during visits to reduce confounding effects. EMG electrodes and IMU sensors will record tremor, while a figure-of-eight TMS coil will deliver phase-locked pulses. Phase-specific stimulation trains are applied for 3 seconds at intervals, with randomized order across multiple blocks. Study sessions last under two hours, including setup and post-stimulation recordings.\n\nParticipants are recruited via self-referral or through DeNDRoN, screened for eligibility, and provide informed consent. Inclusion criteria require symptomatic ET or PD tremor, age ≥18, and ability to consent. Exclusion criteria include epilepsy, psychiatric illness, metal implants, pacemakers, or other conditions contraindicating TMS. Participants may withdraw at any time without penalty.\n\nSafety Measures: TMS and IMU recordings are low-risk, with potential minor effects including scalp tapping sensations, muscle twitches, or mild headaches, which are managed through monitoring and coil adjustment. Serious adverse events are defined, and procedures for reporting and auditing are established in accordance with UK regulations and Good Clinical Practice.\n\nData Analysis: Tremor power will be quantified from IMU recordings using spectral analysis. Statistical comparisons between stimulation conditions and baseline will be conducted using paired t-tests or Wilcoxon tests. The study will employ validated software for randomization and analysis (SPSS, Matlab). Data will be pseudo-anonymized, securely stored, and archived for long-term research use.\n\nEthical Considerations: The study follows the Declaration of Helsinki, Good Clinical Practice, and institutional approvals. Participants' privacy and data protection are ensured under GDPR standards. There are no commercial conflicts of interest, and participants are reimbursed for travel expenses.\n\nIn summary, this research aims to evaluate the efficacy of phase-locked TMS as a non-invasive, targeted interventionfor tremor in ET and PD. By systematically stimulating the motor cortex at tremor-specific phases, the study seeks to establish a foundation for future minimally invasive treatments that could complement or replace existing pharmacological and surgical options.",[594,595],"Essential Tremor","Parkinson's Disease (PD)",[597],"tremor",{"date":599,"type":41},"2026-05-07",{"date":601,"type":41},"2024-01-01",{"date":603,"type":23},"2028-01-01",{"name":47,"class":48},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":612,"targetDuration":4,"studyType":61,"phases":614,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":49},"100594662","investigating-the-neuropsychological-effects-of-5-ht2a-antagonism-100594662","NCT07022366","Investigating the Neuropsychological Effects of 5-HT2a Antagonism","PANDER","Inclusion Criteria:\n\n* Willing and able to give informed consent for participation in the research\n* Aged 18-45 years\n* Good vision and hearing\n* Body mass index (BMI) within the range of 18-35kg\u002Fm2 (This is to ensure an appropriate pharmacokinetic profile for pimavanserin is achieved by all participants)\n* Sufficiently fluent in English to understand tasks\n* Willing to avoid drinking any alcohol the day before the research visit\n\nExclusion Criteria:\n\n* Currently receiving or seeking treatment for any mental health condition\n* Any past or current history of severe and\u002For serious psychiatric disorder, including but not limited to schizophrenia, psychosis, bipolar affective disorder, severe major depressive disorder, obsessive compulsive disorder (covered in SCID-5 assessment in screening procedures)\n* ADHD requiring treatment with stimulant or other centrally-acting drugs\n* Regular alcohol consumption of more than 21 units per week\n* A head injury causing concussion or unconsciousness in the past 6 months\n* Pregnancy \u002F intention to become pregnant during the study or breastfeeding\n* Any use of recreational drugs in the last three months\n* Participation in any other drug study in the last three months\n* Participation in any other study with the same tasks in the last year\n* History of cardiac disease or cardiac arrhythmias\n* Prolonged QTc interval on baseline ECG\n* Current usage of other drugs known to prolong QT interval including Class 1A or 3 antiarrhythmics, e.g. certain antibiotics (getifloxacin, moxifloxacin)\n* Current use of drugs that inhibit CYP3A4 (eg Clarithromycin. Diltiazem. Erythromycin. Fluconazole). Participants will be asked to avoid grapefruit juice in the week before the study.\n* Current use of psychoactive medication that in the opinion of the Chief Investigator may interfere with the study measures\n* History of, or current medical condition(s) which, in the opinion of the Investigator may interfere with the safety of the participant or the scientific integrity of the study, including epilepsy\u002Fseizures, brain injury, severe hepatic or renal disease, severe gastro-intestinal problems, Central Nervous System (CNS) tumours, severe neurological problems (e.g. Parkinson's disease; blackouts requiring hospitalisation);\n* Any physical (including visual and auditory), cognitive or language impairment that would make complying with the study protocol challenging\n* Excessive caffeine consumption, i.e., consumption higher than 8 cups of standard caffeinated drinks (tea, instant coffee) or higher than 6 cups of stronger coffee or other drinks containing methylxanthines such as coca cola or Red Bull per day;\n* Smoking \\>10 cigarettes per day; or equivalent nicotine consumption\n* Participant who is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the chief investigator.\n* Inability to ingest up to 95mg of lactose\n\nAdditional Exclusion Criteria for Participants in the Sleep Study Cohort:\n\n* Unable to undergo cardiac monitoring\n* Unable to wear the sleep patch device for full monitoring period\n* Implanted neurostimulator",{"count":613,"type":23},80,[111],"Serotonin is an important chemical in the brain that helps control mood, sleep, and appetite. Most antidepressant medications work by affecting serotonin to help improve symptoms. A serotonin receptor is like a \"lock\" on the surface of brain cells, and serotonin acts like a \"key\" that fits into these locks. When serotonin binds to the receptor, it sends a signal that helps control different functions in the brain, like mood and behavior. There are different types of serotonin receptors, and each one affects different parts of the brain. Pimavanserin is a medication licensed in the United States of America for the treatment of patients with Parkinson's Disease. It has a very specific effect on one type of serotonin receptor (the serotonin 2a receptor). In this study, the investigators will use pimavanserin to understand more about this serotonin receptor, which may help develop new treatments for depression in the future. More specifically, the study will focus on how pimavanserin impacts cognitive functions such as memory, how we process emotional information and how we make decisions, and will compare these effects to a placebo (a treatment that doesn't have active ingredients).",[617],"Healthy",[619,620],"serotonin 2a","pimavanserin","2026-04-28",{"date":623,"type":41},"2026-04-29",{"date":625,"type":41},"2025-02-10",{"date":627,"type":23},"2026-09",{"name":47,"class":48},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":265,"minAge":637,"maxAge":638,"enrollmentInfo":639,"targetDuration":641,"studyType":25,"phases":4,"briefSummary":642,"conditions":643,"keywords":647,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":654,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":49},"100530456","hypertension-explored-in-long-term-postpartum-follow-up-in-later-life-100530456","NCT06187012","Hypertension Explored in Long-term Postpartum Follow-up in Later Life","Hypertension Explored in Long-term Postpartum Follow-up in Later Life (HELPFUL)","HELPFUL","Inclusion Criteria:\n\n* Inclusion Criteria\n\n  * Participant is willing and able to give informed consent for participation in the study\n  * Female who had a pregnancy 10 to 25 years prior\n  * Able (in the investigator's opinion) and willing to comply with all study requirements.\n  * Adequate understanding of verbal and written English\n\nExclusion Criteria:\n\n* The participant may not enter the study if ANY of the following apply:\n\n  * Over 10 weeks pregnant during the course of the study\n  * Evidence of congenital heart disease or significant chronic disease relevant to cardiovascular or metabolic status\n  * Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study\n\nFor exclusion of MRI component only:\n\n• Unsuitable for MRI based on the responses to the MRI screening form. The participant may still be included in other parts of the study.","30 Years","70 Years",{"count":640,"type":23},200,"40 Years","The purpose of this study is to understand more about why women who have had hypertensive pregnancies may be at increased risk of high blood pressure and why these women are often at increased risk of heart and blood vessel disease later in life.",[644,214,645,646],"Hypertension","Cerebrovascular Disorders","Vascular Diseases",[648,649,270,650,651,652,653],"Hypertensive pregnancy","Older adults","Gestational hypertension","Cardiovascular risk","Disease progression","Longitudinal",{"date":623,"type":41},{"date":656,"type":41},"2023-03-23",{"date":658,"type":23},"2042-11-01",{"name":47,"class":48},""]